{"transactions":[{"id":725612,"issuer":{"id":5311,"kind":"organization","name":"Contineum Therapeutics, Inc.","symbol":"CTNM"},"owners":[{"id":35187,"kind":"person","name":"Ignelzi Troy A.","position":1,"cik":"0001579829","reported_name":"Ignelzi Troy A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-06-26T21:43:48.000Z","date":"2026-06-26","kind":"grant","planned":false,"acquired":true,"shares":19000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Options granted under the Issuer's 2024 Equity Incentive Plan (the \"Plan\"), pursuant to the Issuer's Non-Employee Director Compensation Program, as amended, which states that upon the conclusion of each regular annual meeting of the Company's stockholders, each non-employee director who continues to serve as a member of the Company's Board of Directors thereafter will automatically be granted a stock option under the Plan for 19,000 shares of the Company's Class A Common Stock. Option will vest in full on the earlier of (i) June 26, 2027, the one-year anniversary of the date of grant, or (ii) the next regular annual meeting of stockholders, subject to the Reporting Person's continuous service."}],"balance_after":19000,"derivative":{"exercise_price":14.19,"expiration_date":"2036-06-25","underlying":"Class A Common Stock","underlying_shares":19000},"source":{"system":"sec-edgar","filing":"0001628280-26-045837","document":"wk-form4_1782510226.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1855175/000162828026045837/wk-form4_1782510226.xml","form_type":"4"}},{"id":814217,"issuer":{"id":4381,"kind":"organization","name":"Harmony Biosciences Holdings, Inc.","symbol":"HRMY"},"owners":[{"id":35187,"kind":"person","name":"Ignelzi Troy A.","position":1,"cik":"0001579829","reported_name":"Ignelzi Troy A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2026-04-06T20:14:04.000Z","date":"2026-04-02","kind":"grant","planned":false,"acquired":true,"shares":17710,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option shall vest in 36 equal monthly installments beginning on May 2, 2026."}],"balance_after":17710,"derivative":{"exercise_price":27.74,"expiration_date":"2036-04-02","underlying":"Common Stock","underlying_shares":17710},"source":{"system":"sec-edgar","filing":"0001579829-26-000003","document":"form4-04062026_080459.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1579829/000157982926000003/form4-04062026_080459.xml","form_type":"4"}},{"id":919665,"issuer":{"id":4394,"kind":"organization","name":"Rapport Therapeutics, Inc.","symbol":"RAPP"},"owners":[{"id":35187,"kind":"person","name":"Ignelzi Troy A.","position":1,"cik":"0001579829","reported_name":"Ignelzi Troy A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-02-04T21:12:21.000Z","date":"2026-02-02","kind":"grant","planned":false,"acquired":true,"shares":148000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option shall vest and become exercisable in forty-eight (48) equal monthly installments following January 1, 2026, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":148000,"derivative":{"exercise_price":27.75,"expiration_date":"2036-02-02","underlying":"Common Stock","underlying_shares":148000},"source":{"system":"sec-edgar","filing":"0001193125-26-037587","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2012593/000119312526037587/ownership.xml","form_type":"4"}},{"id":1101137,"issuer":{"id":5311,"kind":"organization","name":"Contineum Therapeutics, Inc.","symbol":"CTNM"},"owners":[{"id":35187,"kind":"person","name":"Ignelzi Troy A.","position":1,"cik":"0001579829","reported_name":"Ignelzi Troy A.","relationship":{"director":true}}],"security":"Stock Option (right to buy)","published_at":"2025-06-26T21:44:32.000Z","date":"2025-06-26","kind":"grant","planned":false,"acquired":true,"shares":14750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Options granted under the Issuer's 2024 Equity Incentive Plan (the \"Plan\"), pursuant to the Issuer's Non-Employee Director Compensation Program, as amended, which states that upon the conclusion of each regular annual meeting of the Company's stockholders, each non-employee director who continues to serve as a member of the Company's Board of Directors thereafter will automatically be granted a stock option under the Plan for 14,750 shares of the Company's Class A Common Stock. Option will vest in full on the earlier of (i) June 26, 2026, the one-year anniversary of the date of grant, or (ii) the next regular annual meeting of stockholders, subject to the Reporting Person's continuous service."}],"balance_after":14750,"derivative":{"exercise_price":4.01,"expiration_date":"2035-06-25","underlying":"Class A Common Stock","underlying_shares":14750},"source":{"system":"sec-edgar","filing":"0001437749-25-021369","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1855175/000143774925021369/rdgdoc.xml","form_type":"4"}},{"id":1208058,"issuer":{"id":4394,"kind":"organization","name":"Rapport Therapeutics, Inc.","symbol":"RAPP"},"owners":[{"id":35187,"kind":"person","name":"Ignelzi Troy A.","position":1,"cik":"0001579829","reported_name":"Ignelzi Troy A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-03-13T21:13:57.000Z","date":"2025-03-13","kind":"purchase","planned":false,"acquired":true,"shares":100,"price":9.98,"value":998.0,"ownership":{"direct":true},"balance_after":10000,"source":{"system":"sec-edgar","filing":"0000950170-25-038878","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2012593/000095017025038878/ownership.xml","form_type":"4"}},{"id":1208057,"issuer":{"id":4394,"kind":"organization","name":"Rapport Therapeutics, Inc.","symbol":"RAPP"},"owners":[{"id":35187,"kind":"person","name":"Ignelzi Troy A.","position":1,"cik":"0001579829","reported_name":"Ignelzi Troy A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-03-13T21:13:57.000Z","date":"2025-03-12","kind":"purchase","planned":false,"acquired":true,"shares":9900,"price":10.1,"value":99990.0,"ownership":{"direct":true},"balance_after":9900,"source":{"system":"sec-edgar","filing":"0000950170-25-038878","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2012593/000095017025038878/ownership.xml","form_type":"4"}},{"id":1285300,"issuer":{"id":4394,"kind":"organization","name":"Rapport Therapeutics, Inc.","symbol":"RAPP"},"owners":[{"id":35187,"kind":"person","name":"Ignelzi Troy A.","position":1,"cik":"0001579829","reported_name":"Ignelzi Troy A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-04T22:30:09.000Z","date":"2025-02-03","kind":"grant","planned":false,"acquired":true,"shares":142000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option shall vest and become exercisable in forty-eight (48) equal monthly installments following January 1, 2025, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":142000,"derivative":{"exercise_price":16.6,"expiration_date":"2035-02-03","underlying":"Common Stock","underlying_shares":142000},"source":{"system":"sec-edgar","filing":"0000950170-25-013754","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2012593/000095017025013754/ownership.xml","form_type":"4"}},{"id":1485266,"issuer":{"id":4394,"kind":"organization","name":"Rapport Therapeutics, Inc.","symbol":"RAPP"},"owners":[{"id":35187,"kind":"person","name":"Ignelzi Troy A.","position":1,"cik":"0001579829","reported_name":"Ignelzi Troy A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-10T23:35:36.000Z","date":"2024-06-06","kind":"grant","planned":false,"acquired":true,"shares":81366,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares underlying this option shall vest and become exercisable on June 6, 2025, with the remaining shares vesting in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":81366,"derivative":{"exercise_price":17,"expiration_date":"2034-06-05","underlying":"Common Stock","underlying_shares":81366},"source":{"system":"sec-edgar","filing":"0000950170-24-071527","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2012593/000095017024071527/ownership.xml","form_type":"4"}},{"id":1499284,"issuer":{"id":5311,"kind":"organization","name":"Contineum Therapeutics, Inc.","symbol":"CTNM"},"owners":[{"id":35187,"kind":"person","name":"Ignelzi Troy A.","position":1,"cik":"0001579829","reported_name":"Ignelzi Troy A.","relationship":{"director":true}}],"security":"Stock Option (right to buy)","published_at":"2024-05-29T21:56:10.000Z","date":"2024-05-24","kind":"grant","planned":false,"acquired":true,"shares":6350,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Options granted under the Issuer's 2024 Equity Incentive Plan, pursuant to the Issuer's Non-Employee Director Compensation Program, as amended. One-third of the option shares vest on May 20, 2025, and the remainder vests in 24 equal monthly installments thereafter, subject to the Reporting Person's continuous service."}],"balance_after":6350,"derivative":{"exercise_price":15.76,"expiration_date":"2034-05-23","underlying":"Class A Common Stock","underlying_shares":6350},"source":{"system":"sec-edgar","filing":"0001437749-24-018622","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1855175/000143774924018622/rdgdoc.xml","form_type":"4"}},{"id":1509129,"issuer":{"id":5311,"kind":"organization","name":"Contineum Therapeutics, Inc.","symbol":"CTNM"},"owners":[{"id":35187,"kind":"person","name":"Ignelzi Troy A.","position":1,"cik":"0001579829","reported_name":"Ignelzi Troy A.","relationship":{"director":true}}],"security":"Stock Option (right to buy)","published_at":"2024-05-20T23:00:38.000Z","date":"2024-05-20","kind":"grant","planned":false,"acquired":true,"shares":23150,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Options granted under the Issuer's 2024 Equity Incentive Plan, pursuant to the Issuer's Non-Employee Director Compensation Plan. One-third of the option shares vest and become exercisable on May 20, 2025, and the remainder vests in 24 equal monthly installments thereafter, subject to the Reporting Person's continuous service."}],"balance_after":23150,"derivative":{"exercise_price":15.71,"expiration_date":"2034-05-19","underlying":"Class A Common Stock","underlying_shares":23150},"source":{"system":"sec-edgar","filing":"0001437749-24-017719","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1855175/000143774924017719/rdgdoc.xml","form_type":"4"}},{"id":1797419,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":35187,"kind":"person","name":"Ignelzi Troy A.","position":1,"cik":"0001579829","reported_name":"Ignelzi Troy A.","relationship":{"officer":true,"officer_title":"Chief Financial Officer"}}],"security":"Option (right to buy)","published_at":"2023-08-24T20:49:56.000Z","date":"2023-08-22","kind":"exercise","planned":true,"acquired":false,"shares":1500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 12, 2022."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"This option vested as to 25% of the shares on the first anniversary of the vesting commencement date of March 1, 2019, with additional vesting as to 12.5% of the shares underlying the option award on each six month period thereafter."}],"balance_after":93226,"derivative":{"exercise_price":9.2,"expiration_date":"2029-03-21","underlying":"Common Stock","underlying_shares":1500},"source":{"system":"sec-edgar","filing":"0000950170-23-044413","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1579829/000095017023044413/ownership.xml","form_type":"4"}},{"id":1797418,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":35187,"kind":"person","name":"Ignelzi Troy A.","position":1,"cik":"0001579829","reported_name":"Ignelzi Troy A.","relationship":{"officer":true,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2023-08-24T20:49:56.000Z","date":"2023-08-22","kind":"sale","planned":true,"acquired":false,"shares":60,"price":176.6,"value":10596.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 12, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $176.59 to $176.61, inclusive."}],"balance_after":30487,"source":{"system":"sec-edgar","filing":"0000950170-23-044413","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1579829/000095017023044413/ownership.xml","form_type":"4"}},{"id":1797417,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":35187,"kind":"person","name":"Ignelzi Troy A.","position":1,"cik":"0001579829","reported_name":"Ignelzi Troy A.","relationship":{"officer":true,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2023-08-24T20:49:56.000Z","date":"2023-08-22","kind":"sale","planned":true,"acquired":false,"shares":505,"price":175.59,"value":88672.95,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 12, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $175.32 to $176.30, inclusive."}],"balance_after":30547,"source":{"system":"sec-edgar","filing":"0000950170-23-044413","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1579829/000095017023044413/ownership.xml","form_type":"4"}},{"id":1797416,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":35187,"kind":"person","name":"Ignelzi Troy A.","position":1,"cik":"0001579829","reported_name":"Ignelzi Troy A.","relationship":{"officer":true,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2023-08-24T20:49:56.000Z","date":"2023-08-22","kind":"sale","planned":true,"acquired":false,"shares":855,"price":174.88,"value":149522.4,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 12, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $174.32 to $175.31, inclusive."}],"balance_after":31052,"source":{"system":"sec-edgar","filing":"0000950170-23-044413","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1579829/000095017023044413/ownership.xml","form_type":"4"}},{"id":1797415,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":35187,"kind":"person","name":"Ignelzi Troy A.","position":1,"cik":"0001579829","reported_name":"Ignelzi Troy A.","relationship":{"officer":true,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2023-08-24T20:49:56.000Z","date":"2023-08-22","kind":"sale","planned":true,"acquired":false,"shares":80,"price":173.64,"value":13891.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 12, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $173.31 to $174.16, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnotes (2) through (5) to this Form 4."}],"balance_after":31907,"source":{"system":"sec-edgar","filing":"0000950170-23-044413","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1579829/000095017023044413/ownership.xml","form_type":"4"}},{"id":1797414,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":35187,"kind":"person","name":"Ignelzi Troy A.","position":1,"cik":"0001579829","reported_name":"Ignelzi Troy A.","relationship":{"officer":true,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2023-08-24T20:49:56.000Z","date":"2023-08-22","kind":"exercise","planned":true,"acquired":true,"shares":1500,"price":9.2,"value":13800.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 12, 2022."}],"balance_after":31987,"source":{"system":"sec-edgar","filing":"0000950170-23-044413","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1579829/000095017023044413/ownership.xml","form_type":"4"}},{"id":1877691,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":35187,"kind":"person","name":"Ignelzi Troy A.","position":1,"cik":"0001579829","reported_name":"Ignelzi Troy A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Option (right to buy)","published_at":"2023-05-25T21:00:36.000Z","date":"2023-05-23","kind":"exercise","planned":true,"acquired":false,"shares":9000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"This option vested as to 25% of the shares on the first anniversary of the vesting commencement date of March 1, 2019, with additional vesting as to 12.5% of the shares underlying the option award on each six month period thereafter."}],"balance_after":94726,"derivative":{"exercise_price":9.2,"expiration_date":"2029-03-21","underlying":"Common Stock","underlying_shares":9000},"source":{"system":"sec-edgar","filing":"0000950170-23-024286","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1579829/000095017023024286/ownership.xml","form_type":"4"}},{"id":1877690,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":35187,"kind":"person","name":"Ignelzi Troy A.","position":1,"cik":"0001579829","reported_name":"Ignelzi Troy A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2023-05-25T21:00:36.000Z","date":"2023-05-23","kind":"sale","planned":true,"acquired":false,"shares":782,"price":225.93,"value":176677.26,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 12, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $225.73 to $226.26, inclusive."}],"balance_after":30487,"source":{"system":"sec-edgar","filing":"0000950170-23-024286","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1579829/000095017023024286/ownership.xml","form_type":"4"}},{"id":1877689,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":35187,"kind":"person","name":"Ignelzi Troy A.","position":1,"cik":"0001579829","reported_name":"Ignelzi Troy A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2023-05-25T21:00:36.000Z","date":"2023-05-23","kind":"sale","planned":true,"acquired":false,"shares":1022,"price":225.19,"value":230144.18,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 12, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $224.73 to $225.66, inclusive."}],"balance_after":31269,"source":{"system":"sec-edgar","filing":"0000950170-23-024286","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1579829/000095017023024286/ownership.xml","form_type":"4"}},{"id":1877688,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":35187,"kind":"person","name":"Ignelzi Troy A.","position":1,"cik":"0001579829","reported_name":"Ignelzi Troy A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2023-05-25T21:00:36.000Z","date":"2023-05-23","kind":"sale","planned":true,"acquired":false,"shares":1070,"price":224.19,"value":239883.3,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 12, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $223.72 to $224.71, inclusive."}],"balance_after":32291,"source":{"system":"sec-edgar","filing":"0000950170-23-024286","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1579829/000095017023024286/ownership.xml","form_type":"4"}},{"id":1877687,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":35187,"kind":"person","name":"Ignelzi Troy A.","position":1,"cik":"0001579829","reported_name":"Ignelzi Troy A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2023-05-25T21:00:36.000Z","date":"2023-05-23","kind":"sale","planned":true,"acquired":false,"shares":3309,"price":223.21,"value":738601.89,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 12, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $222.72 to $223.69, inclusive."}],"balance_after":33361,"source":{"system":"sec-edgar","filing":"0000950170-23-024286","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1579829/000095017023024286/ownership.xml","form_type":"4"}},{"id":1877686,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":35187,"kind":"person","name":"Ignelzi Troy A.","position":1,"cik":"0001579829","reported_name":"Ignelzi Troy A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2023-05-25T21:00:36.000Z","date":"2023-05-23","kind":"sale","planned":true,"acquired":false,"shares":2093,"price":222.24,"value":465148.32,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 12, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $221.72 to $222.71, inclusive."}],"balance_after":36670,"source":{"system":"sec-edgar","filing":"0000950170-23-024286","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1579829/000095017023024286/ownership.xml","form_type":"4"}},{"id":1877685,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":35187,"kind":"person","name":"Ignelzi Troy A.","position":1,"cik":"0001579829","reported_name":"Ignelzi Troy A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2023-05-25T21:00:36.000Z","date":"2023-05-23","kind":"sale","planned":true,"acquired":false,"shares":724,"price":221.28,"value":160206.72,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 12, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $220.72 to $221.71, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnotes (2) through (7) to this Form 4."}],"balance_after":38763,"source":{"system":"sec-edgar","filing":"0000950170-23-024286","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1579829/000095017023024286/ownership.xml","form_type":"4"}},{"id":1877684,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":35187,"kind":"person","name":"Ignelzi Troy A.","position":1,"cik":"0001579829","reported_name":"Ignelzi Troy A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2023-05-25T21:00:36.000Z","date":"2023-05-23","kind":"exercise","planned":true,"acquired":true,"shares":9000,"price":9.2,"value":82800.0,"ownership":{"direct":true},"balance_after":39487,"source":{"system":"sec-edgar","filing":"0000950170-23-024286","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1579829/000095017023024286/ownership.xml","form_type":"4"}},{"id":1992415,"issuer":{"id":116342,"kind":"organization","name":"CinCor Pharma, Inc.","symbol":"CINC"},"owners":[{"id":35187,"kind":"person","name":"Ignelzi Troy A.","position":1,"cik":"0001579829","reported_name":"Ignelzi Troy A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-02-24T23:40:01.000Z","date":"2023-02-24","kind":"disposition_to_issuer","acquired":false,"shares":58823,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of January 8, 2023, by and among CinCor Pharma, Inc. (the \"Issuer\"), AstraZeneca Finance and Holdings Inc. (\"Parent\") and Cinnamon Acquisition, Inc., a wholly owned subsidiary of Parent (\"Purchaser\"), on February 24, 2023, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a \"Share\") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"At the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option with an exercise price less than $26.00 per share (the \"Cash Amount\") was accelerated and became fully vested and exercisable and was cancelled and automatically converted into the right to receive, without interest, (i) cash in an amount equal to the product of (1) the total number of Shares subject to such option as of immediately prior to the effective time of the merger multiplied by (2) the excess of the Cash Amount over the exercise price payable per Share under such option, and (ii) one contingent value right per Share subject to such option, representing the right to receive a contingent payment of $10.00 per share, in cash, upon the achievement of a specified milestone by December 31, 2033."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"At the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option with an exercise price less than $26.00 per share (the \"Cash Amount\") was accelerated and became fully vested and exercisable and was cancelled and automatically converted into the right to receive, without interest, (i) cash in an amount equal to the product of (1) the total number of Shares subject to such option as of immediately prior to the effective time of the merger multiplied by (2) the excess of the Cash Amount over the exercise price payable per Share under such option, and (ii) one contingent value right per Share subject to such option, representing the right to receive a contingent payment of $10.00 per share, in cash, upon the achievement of a specified milestone by December 31, 2033."}],"balance_after":0,"derivative":{"exercise_price":13.6,"expiration_date":"2031-12-09","underlying":"Common Stock","underlying_shares":58823},"source":{"system":"sec-edgar","filing":"0001209191-23-012898","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1579829/000120919123012898/doc4.xml","form_type":"4"}},{"id":1992414,"issuer":{"id":116342,"kind":"organization","name":"CinCor Pharma, Inc.","symbol":"CINC"},"owners":[{"id":35187,"kind":"person","name":"Ignelzi Troy A.","position":1,"cik":"0001579829","reported_name":"Ignelzi Troy A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-02-24T23:40:01.000Z","date":"2023-02-24","kind":"disposition_to_issuer","acquired":false,"shares":36324,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of January 8, 2023, by and among CinCor Pharma, Inc. (the \"Issuer\"), AstraZeneca Finance and Holdings Inc. (\"Parent\") and Cinnamon Acquisition, Inc., a wholly owned subsidiary of Parent (\"Purchaser\"), on February 24, 2023, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a \"Share\") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"At the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option with an exercise price less than $26.00 per share (the \"Cash Amount\") was accelerated and became fully vested and exercisable and was cancelled and automatically converted into the right to receive, without interest, (i) cash in an amount equal to the product of (1) the total number of Shares subject to such option as of immediately prior to the effective time of the merger multiplied by (2) the excess of the Cash Amount over the exercise price payable per Share under such option, and (ii) one contingent value right per Share subject to such option, representing the right to receive a contingent payment of $10.00 per share, in cash, upon the achievement of a specified milestone by December 31, 2033."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"At the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option with an exercise price less than $26.00 per share (the \"Cash Amount\") was accelerated and became fully vested and exercisable and was cancelled and automatically converted into the right to receive, without interest, (i) cash in an amount equal to the product of (1) the total number of Shares subject to such option as of immediately prior to the effective time of the merger multiplied by (2) the excess of the Cash Amount over the exercise price payable per Share under such option, and (ii) one contingent value right per Share subject to such option, representing the right to receive a contingent payment of $10.00 per share, in cash, upon the achievement of a specified milestone by December 31, 2033."}],"balance_after":0,"derivative":{"exercise_price":5.82,"expiration_date":"2031-06-17","underlying":"Common Stock","underlying_shares":36324},"source":{"system":"sec-edgar","filing":"0001209191-23-012898","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1579829/000120919123012898/doc4.xml","form_type":"4"}},{"id":1995321,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":35187,"kind":"person","name":"Ignelzi Troy A.","position":1,"cik":"0001579829","reported_name":"Ignelzi Troy A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Option (right to buy)","published_at":"2023-02-23T21:37:23.000Z","date":"2023-02-21","kind":"exercise","acquired":false,"shares":6000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option vested as to 25% of the shares on the first anniversary of the vesting commencement date of March 1, 2019, with additional vesting as to 12.5% of the shares underlying the option award on each six month period thereafter."}],"balance_after":103726,"derivative":{"exercise_price":9.2,"expiration_date":"2029-03-21","underlying":"Common Stock","underlying_shares":6000},"source":{"system":"sec-edgar","filing":"0001593968-23-000345","document":"primary_01.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1579829/000159396823000345/primary_01.xml","form_type":"4"}},{"id":1995320,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":35187,"kind":"person","name":"Ignelzi Troy A.","position":1,"cik":"0001579829","reported_name":"Ignelzi Troy A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2023-02-23T21:37:23.000Z","date":"2023-02-21","kind":"sale","acquired":false,"shares":6000,"price":190.01,"value":1140060.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 12, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $189.96 to $190.07, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."}],"balance_after":30487,"source":{"system":"sec-edgar","filing":"0001593968-23-000345","document":"primary_01.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1579829/000159396823000345/primary_01.xml","form_type":"4"}},{"id":1995319,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":35187,"kind":"person","name":"Ignelzi Troy A.","position":1,"cik":"0001579829","reported_name":"Ignelzi Troy A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2023-02-23T21:37:23.000Z","date":"2023-02-21","kind":"exercise","acquired":true,"shares":6000,"price":9.2,"value":55200.0,"ownership":{"direct":true},"balance_after":36487,"source":{"system":"sec-edgar","filing":"0001593968-23-000345","document":"primary_01.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1579829/000159396823000345/primary_01.xml","form_type":"4"}},{"id":2019414,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":35187,"kind":"person","name":"Ignelzi Troy A.","position":1,"cik":"0001579829","reported_name":"Ignelzi Troy A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Option (right to buy)","published_at":"2023-02-13T21:39:38.000Z","date":"2023-02-09","kind":"grant","acquired":true,"shares":17350,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"25% of this option shall vest on February 9, 2024, and the remaining 75% shall vest in twelve equal three-month installments over the following three years, subject to continued service through such dates."}],"balance_after":17350,"derivative":{"exercise_price":187.26,"expiration_date":"2033-02-08","underlying":"Common Stock","underlying_shares":17350},"source":{"system":"sec-edgar","filing":"0001593968-23-000304","document":"primary_01.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1579829/000159396823000304/primary_01.xml","form_type":"4"}},{"id":2019413,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":35187,"kind":"person","name":"Ignelzi Troy A.","position":1,"cik":"0001579829","reported_name":"Ignelzi Troy A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2023-02-13T21:39:38.000Z","date":"2023-02-09","kind":"grant","acquired":true,"shares":8650,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Comprised of restricted stock units (\"RSUs\"), each representing a contingent right to receive one share of the Issuer's common stock. The RSUs shall vest annually in four 25% installments commencing on February 9, 2024, subject to continued service through such dates."}],"balance_after":30487,"source":{"system":"sec-edgar","filing":"0001593968-23-000304","document":"primary_01.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1579829/000159396823000304/primary_01.xml","form_type":"4"}},{"id":2050445,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":35187,"kind":"person","name":"Ignelzi Troy A.","position":1,"cik":"0001579829","reported_name":"Ignelzi Troy A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Option (right to buy)","published_at":"2023-01-19T21:45:55.000Z","date":"2023-01-18","kind":"exercise","acquired":false,"shares":200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option vested as to 25% of the shares on the first anniversary of the vesting commencement date of March 1, 2019, with additional vesting as to 12.5% of the shares underlying the option award on each six month period thereafter."}],"balance_after":109726,"derivative":{"exercise_price":9.2,"expiration_date":"2029-03-21","underlying":"Common Stock","underlying_shares":200},"source":{"system":"sec-edgar","filing":"0001593968-23-000170","document":"primary_01.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1579829/000159396823000170/primary_01.xml","form_type":"4"}},{"id":2050444,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":35187,"kind":"person","name":"Ignelzi Troy A.","position":1,"cik":"0001579829","reported_name":"Ignelzi Troy A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Option (right to buy)","published_at":"2023-01-19T21:45:55.000Z","date":"2023-01-17","kind":"exercise","acquired":false,"shares":817,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option vested as to 25% of the shares on the first anniversary of the vesting commencement date of March 1, 2019, with additional vesting as to 12.5% of the shares underlying the option award on each six month period thereafter."}],"balance_after":109926,"derivative":{"exercise_price":9.2,"expiration_date":"2029-03-21","underlying":"Common Stock","underlying_shares":817},"source":{"system":"sec-edgar","filing":"0001593968-23-000170","document":"primary_01.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1579829/000159396823000170/primary_01.xml","form_type":"4"}},{"id":2050443,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":35187,"kind":"person","name":"Ignelzi Troy A.","position":1,"cik":"0001579829","reported_name":"Ignelzi Troy A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2023-01-19T21:45:55.000Z","date":"2023-01-18","kind":"sale","acquired":false,"shares":200,"price":200.14,"value":40028.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 12, 2022."}],"balance_after":21837,"source":{"system":"sec-edgar","filing":"0001593968-23-000170","document":"primary_01.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1579829/000159396823000170/primary_01.xml","form_type":"4"}},{"id":2050442,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":35187,"kind":"person","name":"Ignelzi Troy A.","position":1,"cik":"0001579829","reported_name":"Ignelzi Troy A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2023-01-19T21:45:55.000Z","date":"2023-01-18","kind":"exercise","acquired":true,"shares":200,"price":9.2,"value":1840.0,"ownership":{"direct":true},"balance_after":22037,"source":{"system":"sec-edgar","filing":"0001593968-23-000170","document":"primary_01.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1579829/000159396823000170/primary_01.xml","form_type":"4"}},{"id":2050441,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":35187,"kind":"person","name":"Ignelzi Troy A.","position":1,"cik":"0001579829","reported_name":"Ignelzi Troy A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2023-01-19T21:45:55.000Z","date":"2023-01-17","kind":"sale","acquired":false,"shares":817,"price":201.41,"value":164551.97,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 12, 2022."}],"balance_after":21837,"source":{"system":"sec-edgar","filing":"0001593968-23-000170","document":"primary_01.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1579829/000159396823000170/primary_01.xml","form_type":"4"}},{"id":2050440,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":35187,"kind":"person","name":"Ignelzi Troy A.","position":1,"cik":"0001579829","reported_name":"Ignelzi Troy A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2023-01-19T21:45:55.000Z","date":"2023-01-17","kind":"exercise","acquired":true,"shares":817,"price":9.2,"value":7516.4,"ownership":{"direct":true},"balance_after":22654,"source":{"system":"sec-edgar","filing":"0001593968-23-000170","document":"primary_01.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1579829/000159396823000170/primary_01.xml","form_type":"4"}},{"id":2081165,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":35187,"kind":"person","name":"Ignelzi Troy A.","position":1,"cik":"0001579829","reported_name":"Ignelzi Troy A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Option (right to buy)","published_at":"2022-12-19T21:24:16.000Z","date":"2022-12-16","kind":"exercise","acquired":false,"shares":627,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option vested as to 1/36th of the shares underlying the option award on each one month anniversary of the vesting commencement date of March 1, 2019."}],"balance_after":626,"derivative":{"exercise_price":9.2,"expiration_date":"2029-04-07","underlying":"Common Stock","underlying_shares":627},"source":{"system":"sec-edgar","filing":"0001593968-22-001741","document":"primary_01.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1579829/000159396822001741/primary_01.xml","form_type":"4"}},{"id":2081164,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":35187,"kind":"person","name":"Ignelzi Troy A.","position":1,"cik":"0001579829","reported_name":"Ignelzi Troy A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Option (right to buy)","published_at":"2022-12-19T21:24:16.000Z","date":"2022-12-16","kind":"exercise","acquired":false,"shares":371,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option vested as to 1/36th of the shares underlying the option award on each one month anniversary of the vesting commencement date of March 1, 2019."}],"balance_after":8559,"derivative":{"exercise_price":9.2,"expiration_date":"2029-03-28","underlying":"Common Stock","underlying_shares":371},"source":{"system":"sec-edgar","filing":"0001593968-22-001741","document":"primary_01.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1579829/000159396822001741/primary_01.xml","form_type":"4"}},{"id":2081163,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":35187,"kind":"person","name":"Ignelzi Troy A.","position":1,"cik":"0001579829","reported_name":"Ignelzi Troy A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Option (right to buy)","published_at":"2022-12-19T21:24:16.000Z","date":"2022-12-16","kind":"exercise","acquired":false,"shares":10869,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vested and became exercisable as to 1/4th of the shares underlying the option award on March 1, 2020, and continues to vest as to an additional 1/8th of the shares on each six month anniversary thereafter."}],"balance_after":110743,"derivative":{"exercise_price":9.2,"expiration_date":"2029-03-21","underlying":"Common Stock","underlying_shares":10869},"source":{"system":"sec-edgar","filing":"0001593968-22-001741","document":"primary_01.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1579829/000159396822001741/primary_01.xml","form_type":"4"}},{"id":2081162,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":35187,"kind":"person","name":"Ignelzi Troy A.","position":1,"cik":"0001579829","reported_name":"Ignelzi Troy A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2022-12-19T21:24:16.000Z","date":"2022-12-16","kind":"exercise","acquired":true,"shares":627,"price":9.2,"value":5768.4,"ownership":{"direct":true},"balance_after":21837,"source":{"system":"sec-edgar","filing":"0001593968-22-001741","document":"primary_01.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1579829/000159396822001741/primary_01.xml","form_type":"4"}},{"id":2081161,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":35187,"kind":"person","name":"Ignelzi Troy A.","position":1,"cik":"0001579829","reported_name":"Ignelzi Troy A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2022-12-19T21:24:16.000Z","date":"2022-12-16","kind":"exercise","acquired":true,"shares":371,"price":9.2,"value":3413.2,"ownership":{"direct":true},"balance_after":21210,"source":{"system":"sec-edgar","filing":"0001593968-22-001741","document":"primary_01.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1579829/000159396822001741/primary_01.xml","form_type":"4"}},{"id":2081160,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":35187,"kind":"person","name":"Ignelzi Troy A.","position":1,"cik":"0001579829","reported_name":"Ignelzi Troy A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2022-12-19T21:24:16.000Z","date":"2022-12-16","kind":"exercise","acquired":true,"shares":10869,"price":9.2,"value":99994.8,"ownership":{"direct":true},"balance_after":20839,"source":{"system":"sec-edgar","filing":"0001593968-22-001741","document":"primary_01.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1579829/000159396822001741/primary_01.xml","form_type":"4"}},{"id":2111569,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":35187,"kind":"person","name":"Ignelzi Troy A.","position":1,"cik":"0001579829","reported_name":"Ignelzi Troy A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Option (right to buy)","published_at":"2022-11-17T22:08:58.000Z","date":"2022-11-15","kind":"exercise","acquired":false,"shares":16500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option vested as to 25% of the shares on the first anniversary of the vesting commencement date of March 1, 2019, with additional vesting as to 12.5% of the shares underlying the option award on each six month period thereafter."}],"balance_after":121612,"derivative":{"exercise_price":9.2,"expiration_date":"2029-03-21","underlying":"Common Stock","underlying_shares":16500},"source":{"system":"sec-edgar","filing":"0001593968-22-001609","document":"primary_01.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1579829/000159396822001609/primary_01.xml","form_type":"4"}},{"id":2111568,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":35187,"kind":"person","name":"Ignelzi Troy A.","position":1,"cik":"0001579829","reported_name":"Ignelzi Troy A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2022-11-17T22:08:58.000Z","date":"2022-11-15","kind":"sale","acquired":false,"shares":16500,"price":225.85,"value":3726525.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 1, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $225.74 to $225.94, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."}],"balance_after":9970,"source":{"system":"sec-edgar","filing":"0001593968-22-001609","document":"primary_01.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1579829/000159396822001609/primary_01.xml","form_type":"4"}},{"id":2111567,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":35187,"kind":"person","name":"Ignelzi Troy A.","position":1,"cik":"0001579829","reported_name":"Ignelzi Troy A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2022-11-17T22:08:58.000Z","date":"2022-11-15","kind":"exercise","acquired":true,"shares":16500,"price":9.2,"value":151800.0,"ownership":{"direct":true},"balance_after":26470,"source":{"system":"sec-edgar","filing":"0001593968-22-001609","document":"primary_01.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1579829/000159396822001609/primary_01.xml","form_type":"4"}},{"id":2143663,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":35187,"kind":"person","name":"Ignelzi Troy A.","position":1,"cik":"0001579829","reported_name":"Ignelzi Troy A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2022-10-04T23:25:59.000Z","date":"2022-10-04","kind":"sale","acquired":false,"shares":400,"price":233.2,"value":93280.0,"ownership":{"direct":true},"balance_after":9970,"source":{"system":"sec-edgar","filing":"0001593968-22-001490","document":"primary_01.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1579829/000159396822001490/primary_01.xml","form_type":"4"}},{"id":2143662,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":35187,"kind":"person","name":"Ignelzi Troy A.","position":1,"cik":"0001579829","reported_name":"Ignelzi Troy A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2022-10-04T23:25:59.000Z","date":"2022-10-03","kind":"sale","acquired":false,"shares":1100,"price":232,"value":255200.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $232.00 to $232.01, inclusive."}],"balance_after":10370,"source":{"system":"sec-edgar","filing":"0001593968-22-001490","document":"primary_01.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1579829/000159396822001490/primary_01.xml","form_type":"4"}},{"id":2143661,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":35187,"kind":"person","name":"Ignelzi Troy A.","position":1,"cik":"0001579829","reported_name":"Ignelzi Troy A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2022-10-04T23:25:59.000Z","date":"2022-10-03","kind":"sale","acquired":false,"shares":2000,"price":231.3,"value":462600.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $231.00 to $231.55, inclusive."}],"balance_after":11470,"source":{"system":"sec-edgar","filing":"0001593968-22-001490","document":"primary_01.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1579829/000159396822001490/primary_01.xml","form_type":"4"}},{"id":2143660,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":35187,"kind":"person","name":"Ignelzi Troy A.","position":1,"cik":"0001579829","reported_name":"Ignelzi Troy A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2022-10-04T23:25:59.000Z","date":"2022-10-03","kind":"sale","acquired":false,"shares":1000,"price":230.02,"value":230020.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $230.00 to $230.11, inclusive."}],"balance_after":13470,"source":{"system":"sec-edgar","filing":"0001593968-22-001490","document":"primary_01.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1579829/000159396822001490/primary_01.xml","form_type":"4"}},{"id":2143659,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":35187,"kind":"person","name":"Ignelzi Troy A.","position":1,"cik":"0001579829","reported_name":"Ignelzi Troy A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2022-10-04T23:25:59.000Z","date":"2022-09-30","kind":"sale","acquired":false,"shares":33,"price":230.49,"value":7606.17,"ownership":{"direct":true},"balance_after":14470,"source":{"system":"sec-edgar","filing":"0001593968-22-001490","document":"primary_01.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1579829/000159396822001490/primary_01.xml","form_type":"4"}},{"id":2143658,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":35187,"kind":"person","name":"Ignelzi Troy A.","position":1,"cik":"0001579829","reported_name":"Ignelzi Troy A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2022-10-04T23:25:59.000Z","date":"2022-09-30","kind":"sale","acquired":false,"shares":5189,"price":229.77,"value":1192276.53,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $229.45 to $230.42, inclusive."}],"balance_after":14503,"source":{"system":"sec-edgar","filing":"0001593968-22-001490","document":"primary_01.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1579829/000159396822001490/primary_01.xml","form_type":"4"}},{"id":2143657,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":35187,"kind":"person","name":"Ignelzi Troy A.","position":1,"cik":"0001579829","reported_name":"Ignelzi Troy A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2022-10-04T23:25:59.000Z","date":"2022-09-30","kind":"sale","acquired":false,"shares":2819,"price":228.74,"value":644818.06,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $228.31 to $229.27, inclusive."}],"balance_after":19692,"source":{"system":"sec-edgar","filing":"0001593968-22-001490","document":"primary_01.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1579829/000159396822001490/primary_01.xml","form_type":"4"}},{"id":2143656,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":35187,"kind":"person","name":"Ignelzi Troy A.","position":1,"cik":"0001579829","reported_name":"Ignelzi Troy A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2022-10-04T23:25:59.000Z","date":"2022-09-30","kind":"sale","acquired":false,"shares":2459,"price":227.05,"value":558315.95,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $227.00 to $227.95, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1) through (6) to this Form 4."}],"balance_after":22511,"source":{"system":"sec-edgar","filing":"0001593968-22-001490","document":"primary_01.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1579829/000159396822001490/primary_01.xml","form_type":"4"}},{"id":2187801,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":35187,"kind":"person","name":"Ignelzi Troy A.","position":1,"cik":"0001579829","reported_name":"Ignelzi Troy A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Option (right to buy)","published_at":"2022-08-11T21:17:48.000Z","date":"2022-08-09","kind":"exercise","acquired":false,"shares":16500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option vested as to 25% of the shares on the first anniversary of the vesting commencement date of March 1, 2019, with additional vesting as to 12.5% of the shares underlying the option award on each six month period thereafter."}],"balance_after":138112,"derivative":{"exercise_price":9.2,"expiration_date":"2029-03-21","underlying":"Common Stock","underlying_shares":16500},"source":{"system":"sec-edgar","filing":"0001593968-22-001335","document":"primary_01.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1579829/000159396822001335/primary_01.xml","form_type":"4"}},{"id":2187800,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":35187,"kind":"person","name":"Ignelzi Troy A.","position":1,"cik":"0001579829","reported_name":"Ignelzi Troy A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2022-08-11T21:17:48.000Z","date":"2022-08-09","kind":"sale","acquired":false,"shares":16500,"price":227.83,"value":3759195.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 1, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $227.55 to $228.22, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."}],"balance_after":24970,"source":{"system":"sec-edgar","filing":"0001593968-22-001335","document":"primary_01.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1579829/000159396822001335/primary_01.xml","form_type":"4"}},{"id":2187799,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":35187,"kind":"person","name":"Ignelzi Troy A.","position":1,"cik":"0001579829","reported_name":"Ignelzi Troy A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2022-08-11T21:17:48.000Z","date":"2022-08-09","kind":"exercise","acquired":true,"shares":16500,"price":9.2,"value":151800.0,"ownership":{"direct":true},"balance_after":41470,"source":{"system":"sec-edgar","filing":"0001593968-22-001335","document":"primary_01.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1579829/000159396822001335/primary_01.xml","form_type":"4"}},{"id":2292538,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":35187,"kind":"person","name":"Ignelzi Troy A.","position":1,"cik":"0001579829","reported_name":"Ignelzi Troy A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Option (right to buy)","published_at":"2022-04-21T23:04:30.000Z","date":"2022-04-21","kind":"exercise","acquired":false,"shares":40,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option vested as to 25% of the shares on the first anniversary of the vesting commencement date of March 1, 2019, with additional vesting as to 12.5% of the shares underlying the option award on each six month period thereafter."}],"balance_after":154612,"derivative":{"exercise_price":9.2,"expiration_date":"2029-03-21","underlying":"Common Stock","underlying_shares":40},"source":{"system":"sec-edgar","filing":"0001593968-22-000886","document":"primary_01.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1579829/000159396822000886/primary_01.xml","form_type":"4"}},{"id":2292537,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":35187,"kind":"person","name":"Ignelzi Troy A.","position":1,"cik":"0001579829","reported_name":"Ignelzi Troy A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Option (right to buy)","published_at":"2022-04-21T23:04:30.000Z","date":"2022-04-20","kind":"exercise","acquired":false,"shares":704,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option vested as to 25% of the shares on the first anniversary of the vesting commencement date of March 1, 2019, with additional vesting as to 12.5% of the shares underlying the option award on each six month period thereafter."}],"balance_after":154652,"derivative":{"exercise_price":9.2,"expiration_date":"2029-03-21","underlying":"Common Stock","underlying_shares":704},"source":{"system":"sec-edgar","filing":"0001593968-22-000886","document":"primary_01.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1579829/000159396822000886/primary_01.xml","form_type":"4"}},{"id":2292536,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":35187,"kind":"person","name":"Ignelzi Troy A.","position":1,"cik":"0001579829","reported_name":"Ignelzi Troy A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Option (right to buy)","published_at":"2022-04-21T23:04:30.000Z","date":"2022-04-19","kind":"exercise","acquired":false,"shares":3500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option vested as to 25% of the shares on the first anniversary of the vesting commencement date of March 1, 2019, with additional vesting as to 12.5% of the shares underlying the option award on each six month period thereafter."}],"balance_after":155356,"derivative":{"exercise_price":9.2,"expiration_date":"2029-03-21","underlying":"Common Stock","underlying_shares":3500},"source":{"system":"sec-edgar","filing":"0001593968-22-000886","document":"primary_01.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1579829/000159396822000886/primary_01.xml","form_type":"4"}},{"id":2292535,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":35187,"kind":"person","name":"Ignelzi Troy A.","position":1,"cik":"0001579829","reported_name":"Ignelzi Troy A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2022-04-21T23:04:30.000Z","date":"2022-04-21","kind":"sale","acquired":false,"shares":40,"price":134.46,"value":5378.4,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 1, 2022."}],"balance_after":24970,"source":{"system":"sec-edgar","filing":"0001593968-22-000886","document":"primary_01.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1579829/000159396822000886/primary_01.xml","form_type":"4"}},{"id":2292534,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":35187,"kind":"person","name":"Ignelzi Troy A.","position":1,"cik":"0001579829","reported_name":"Ignelzi Troy A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2022-04-21T23:04:30.000Z","date":"2022-04-21","kind":"exercise","acquired":true,"shares":40,"price":9.2,"value":368.0,"ownership":{"direct":true},"balance_after":25010,"source":{"system":"sec-edgar","filing":"0001593968-22-000886","document":"primary_01.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1579829/000159396822000886/primary_01.xml","form_type":"4"}},{"id":2292533,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":35187,"kind":"person","name":"Ignelzi Troy A.","position":1,"cik":"0001579829","reported_name":"Ignelzi Troy A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2022-04-21T23:04:30.000Z","date":"2022-04-20","kind":"sale","acquired":false,"shares":704,"price":133.2,"value":93772.8,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 1, 2022."}],"balance_after":24970,"source":{"system":"sec-edgar","filing":"0001593968-22-000886","document":"primary_01.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1579829/000159396822000886/primary_01.xml","form_type":"4"}},{"id":2292532,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":35187,"kind":"person","name":"Ignelzi Troy A.","position":1,"cik":"0001579829","reported_name":"Ignelzi Troy A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2022-04-21T23:04:30.000Z","date":"2022-04-20","kind":"exercise","acquired":true,"shares":704,"price":9.2,"value":6476.8,"ownership":{"direct":true},"balance_after":25674,"source":{"system":"sec-edgar","filing":"0001593968-22-000886","document":"primary_01.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1579829/000159396822000886/primary_01.xml","form_type":"4"}},{"id":2292531,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":35187,"kind":"person","name":"Ignelzi Troy A.","position":1,"cik":"0001579829","reported_name":"Ignelzi Troy A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2022-04-21T23:04:30.000Z","date":"2022-04-19","kind":"sale","acquired":false,"shares":3500,"price":130.81,"value":457835.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 1, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $130.78 to $130.84, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."}],"balance_after":24970,"source":{"system":"sec-edgar","filing":"0001593968-22-000886","document":"primary_01.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1579829/000159396822000886/primary_01.xml","form_type":"4"}},{"id":2292530,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":35187,"kind":"person","name":"Ignelzi Troy A.","position":1,"cik":"0001579829","reported_name":"Ignelzi Troy A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2022-04-21T23:04:30.000Z","date":"2022-04-19","kind":"exercise","acquired":true,"shares":3500,"price":9.2,"value":32200.0,"ownership":{"direct":true},"balance_after":28470,"source":{"system":"sec-edgar","filing":"0001593968-22-000886","document":"primary_01.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1579829/000159396822000886/primary_01.xml","form_type":"4"}},{"id":2387518,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":35187,"kind":"person","name":"Ignelzi Troy A.","position":1,"cik":"0001579829","reported_name":"Ignelzi Troy A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Option (right to buy)","published_at":"2022-02-17T22:21:04.000Z","date":"2022-02-16","kind":"grant","acquired":true,"shares":48500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"25% of the options shall vest on February 16, 2023, and the remaining options shall vest in twelve equal three-month installments over the following three years, subject to continued service through such dates."}],"balance_after":48500,"derivative":{"exercise_price":111.97,"expiration_date":"2032-02-15","underlying":"Common Stock","underlying_shares":48500},"source":{"system":"sec-edgar","filing":"0001593968-22-000496","document":"primary_01.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1579829/000159396822000496/primary_01.xml","form_type":"4"}},{"id":2387517,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":35187,"kind":"person","name":"Ignelzi Troy A.","position":1,"cik":"0001579829","reported_name":"Ignelzi Troy A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Option (right to buy)","published_at":"2022-02-17T22:21:04.000Z","date":"2022-02-15","kind":"exercise","acquired":false,"shares":1500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option vested as to 25% of the shares on the first anniversary of the vesting commencement date of March 1, 2019, with additional vesting as to 12.5% of the shares underlying the option award on each six month period thereafter."}],"balance_after":158856,"derivative":{"exercise_price":9.2,"expiration_date":"2029-03-21","underlying":"Common Stock","underlying_shares":1500},"source":{"system":"sec-edgar","filing":"0001593968-22-000496","document":"primary_01.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1579829/000159396822000496/primary_01.xml","form_type":"4"}},{"id":2387516,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":35187,"kind":"person","name":"Ignelzi Troy A.","position":1,"cik":"0001579829","reported_name":"Ignelzi Troy A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2022-02-17T22:21:04.000Z","date":"2022-02-15","kind":"sale","acquired":false,"shares":1500,"price":111.14,"value":166710.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 1, 2022."}],"balance_after":24970,"source":{"system":"sec-edgar","filing":"0001593968-22-000496","document":"primary_01.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1579829/000159396822000496/primary_01.xml","form_type":"4"}},{"id":2387515,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":35187,"kind":"person","name":"Ignelzi Troy A.","position":1,"cik":"0001579829","reported_name":"Ignelzi Troy A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2022-02-17T22:21:04.000Z","date":"2022-02-15","kind":"exercise","acquired":true,"shares":1500,"price":9.2,"value":13800.0,"ownership":{"direct":true},"balance_after":26470,"source":{"system":"sec-edgar","filing":"0001593968-22-000496","document":"primary_01.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1579829/000159396822000496/primary_01.xml","form_type":"4"}},{"id":2460536,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":35187,"kind":"person","name":"Ignelzi Troy A.","position":1,"cik":"0001579829","reported_name":"Ignelzi Troy A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Option (right to buy)","published_at":"2021-12-22T21:42:52.000Z","date":"2021-12-21","kind":"exercise","acquired":false,"shares":1101,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option vests and becomes exercisable in thirty-six equal monthly installments beginning on April 1, 2019."}],"balance_after":8930,"derivative":{"exercise_price":9.2,"expiration_date":"2029-03-29","underlying":"Common Stock","underlying_shares":1101},"source":{"system":"sec-edgar","filing":"0001593968-21-002566","document":"primary_01.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1579829/000159396821002566/primary_01.xml","form_type":"4"}},{"id":2460535,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":35187,"kind":"person","name":"Ignelzi Troy A.","position":1,"cik":"0001579829","reported_name":"Ignelzi Troy A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Option (right to buy)","published_at":"2021-12-22T21:42:52.000Z","date":"2021-12-21","kind":"exercise","acquired":false,"shares":5869,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vested and became exercisable as to 1/4th of the shares underlying the option award on March 1, 2020, and continues to vest as to an additional 1/8th of the shares on each six month anniversary thereafter."}],"balance_after":160356,"derivative":{"exercise_price":9.2,"expiration_date":"2029-03-21","underlying":"Common Stock","underlying_shares":5869},"source":{"system":"sec-edgar","filing":"0001593968-21-002566","document":"primary_01.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1579829/000159396821002566/primary_01.xml","form_type":"4"}},{"id":2460534,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":35187,"kind":"person","name":"Ignelzi Troy A.","position":1,"cik":"0001579829","reported_name":"Ignelzi Troy A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-12-22T21:42:52.000Z","date":"2021-12-21","kind":"exercise","acquired":true,"shares":1101,"price":9.2,"value":10129.2,"ownership":{"direct":true},"balance_after":24970,"source":{"system":"sec-edgar","filing":"0001593968-21-002566","document":"primary_01.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1579829/000159396821002566/primary_01.xml","form_type":"4"}},{"id":2460533,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":35187,"kind":"person","name":"Ignelzi Troy A.","position":1,"cik":"0001579829","reported_name":"Ignelzi Troy A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-12-22T21:42:52.000Z","date":"2021-12-21","kind":"exercise","acquired":true,"shares":5869,"price":9.2,"value":53994.8,"ownership":{"direct":true},"balance_after":23869,"source":{"system":"sec-edgar","filing":"0001593968-21-002566","document":"primary_01.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1579829/000159396821002566/primary_01.xml","form_type":"4"}},{"id":2517323,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":35187,"kind":"person","name":"Ignelzi Troy A.","position":1,"cik":"0001579829","reported_name":"Ignelzi Troy A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Option (right to buy)","published_at":"2021-11-10T21:08:10.000Z","date":"2021-11-08","kind":"exercise","acquired":false,"shares":13500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option vested as to 25% of the shares on the first anniversary of the vesting commencement date of March 1, 2019, with additional vesting as to 12.5% of the shares underlying the option award on each six month period thereafter."}],"balance_after":166225,"derivative":{"exercise_price":9.2,"expiration_date":"2029-03-21","underlying":"Common Stock","underlying_shares":13500},"source":{"system":"sec-edgar","filing":"0001593968-21-002380","document":"primary_01.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1579829/000159396821002380/primary_01.xml","form_type":"4"}},{"id":2517322,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":35187,"kind":"person","name":"Ignelzi Troy A.","position":1,"cik":"0001579829","reported_name":"Ignelzi Troy A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-11-10T21:08:10.000Z","date":"2021-11-08","kind":"sale","acquired":false,"shares":13500,"price":152.32,"value":2056320.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 15, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $151.82 to $152.49, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."}],"balance_after":18000,"source":{"system":"sec-edgar","filing":"0001593968-21-002380","document":"primary_01.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1579829/000159396821002380/primary_01.xml","form_type":"4"}},{"id":2517321,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":35187,"kind":"person","name":"Ignelzi Troy A.","position":1,"cik":"0001579829","reported_name":"Ignelzi Troy A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-11-10T21:08:10.000Z","date":"2021-11-08","kind":"exercise","acquired":true,"shares":13500,"price":9.2,"value":124200.0,"ownership":{"direct":true},"balance_after":31500,"source":{"system":"sec-edgar","filing":"0001593968-21-002380","document":"primary_01.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1579829/000159396821002380/primary_01.xml","form_type":"4"}},{"id":2572931,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":35187,"kind":"person","name":"Ignelzi Troy A.","position":1,"cik":"0001579829","reported_name":"Ignelzi Troy A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Option (right to buy)","published_at":"2021-09-10T20:58:56.000Z","date":"2021-09-10","kind":"exercise","acquired":false,"shares":1900,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option vested as to 25% of the shares on the first anniversary of the vesting commencement date of March 1, 2019, with additional vesting as to 12.5% of the shares underlying the option award on each six month period thereafter."}],"balance_after":179725,"derivative":{"exercise_price":9.2,"expiration_date":"2029-03-21","underlying":"Common Stock","underlying_shares":1900},"source":{"system":"sec-edgar","filing":"0001593968-21-002107","document":"primary_01.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1579829/000159396821002107/primary_01.xml","form_type":"4"}},{"id":2572930,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":35187,"kind":"person","name":"Ignelzi Troy A.","position":1,"cik":"0001579829","reported_name":"Ignelzi Troy A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Option (right to buy)","published_at":"2021-09-10T20:58:56.000Z","date":"2021-09-09","kind":"exercise","acquired":false,"shares":500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option vested as to 25% of the shares on the first anniversary of the vesting commencement date of March 1, 2019, with additional vesting as to 12.5% of the shares underlying the option award on each six month period thereafter."}],"balance_after":181625,"derivative":{"exercise_price":9.2,"expiration_date":"2029-03-21","underlying":"Common Stock","underlying_shares":500},"source":{"system":"sec-edgar","filing":"0001593968-21-002107","document":"primary_01.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1579829/000159396821002107/primary_01.xml","form_type":"4"}},{"id":2572929,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":35187,"kind":"person","name":"Ignelzi Troy A.","position":1,"cik":"0001579829","reported_name":"Ignelzi Troy A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Option (right to buy)","published_at":"2021-09-10T20:58:56.000Z","date":"2021-09-08","kind":"exercise","acquired":false,"shares":600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option vested as to 25% of the shares on the first anniversary of the vesting commencement date of March 1, 2019, with additional vesting as to 12.5% of the shares underlying the option award on each six month period thereafter."}],"balance_after":182125,"derivative":{"exercise_price":9.2,"expiration_date":"2029-03-21","underlying":"Common Stock","underlying_shares":600},"source":{"system":"sec-edgar","filing":"0001593968-21-002107","document":"primary_01.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1579829/000159396821002107/primary_01.xml","form_type":"4"}},{"id":2572928,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":35187,"kind":"person","name":"Ignelzi Troy A.","position":1,"cik":"0001579829","reported_name":"Ignelzi Troy A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Option (right to buy)","published_at":"2021-09-10T20:58:56.000Z","date":"2021-09-08","kind":"exercise","acquired":false,"shares":7000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option vested as to 25% of the shares on the first anniversary of the vesting commencement date of March 1, 2019, with additional vesting as to 12.5% of the shares underlying the option award on each six month period thereafter."}],"balance_after":182725,"derivative":{"exercise_price":9.2,"expiration_date":"2029-03-21","underlying":"Common Stock","underlying_shares":7000},"source":{"system":"sec-edgar","filing":"0001593968-21-002107","document":"primary_01.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1579829/000159396821002107/primary_01.xml","form_type":"4"}},{"id":2572927,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":35187,"kind":"person","name":"Ignelzi Troy A.","position":1,"cik":"0001579829","reported_name":"Ignelzi Troy A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-09-10T20:58:56.000Z","date":"2021-09-10","kind":"sale","acquired":false,"shares":1900,"price":120.05,"value":228095.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 15, 2021."}],"balance_after":18000,"source":{"system":"sec-edgar","filing":"0001593968-21-002107","document":"primary_01.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1579829/000159396821002107/primary_01.xml","form_type":"4"}},{"id":2572926,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":35187,"kind":"person","name":"Ignelzi Troy A.","position":1,"cik":"0001579829","reported_name":"Ignelzi Troy A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-09-10T20:58:56.000Z","date":"2021-09-10","kind":"exercise","acquired":true,"shares":1900,"price":9.2,"value":17480.0,"ownership":{"direct":true},"balance_after":19900,"source":{"system":"sec-edgar","filing":"0001593968-21-002107","document":"primary_01.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1579829/000159396821002107/primary_01.xml","form_type":"4"}},{"id":2572925,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":35187,"kind":"person","name":"Ignelzi Troy A.","position":1,"cik":"0001579829","reported_name":"Ignelzi Troy A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-09-10T20:58:56.000Z","date":"2021-09-09","kind":"sale","acquired":false,"shares":500,"price":120.05,"value":60025.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 15, 2021."}],"balance_after":18000,"source":{"system":"sec-edgar","filing":"0001593968-21-002107","document":"primary_01.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1579829/000159396821002107/primary_01.xml","form_type":"4"}},{"id":2572924,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":35187,"kind":"person","name":"Ignelzi Troy A.","position":1,"cik":"0001579829","reported_name":"Ignelzi Troy A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-09-10T20:58:56.000Z","date":"2021-09-09","kind":"exercise","acquired":true,"shares":500,"price":9.2,"value":4600.0,"ownership":{"direct":true},"balance_after":18500,"source":{"system":"sec-edgar","filing":"0001593968-21-002107","document":"primary_01.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1579829/000159396821002107/primary_01.xml","form_type":"4"}},{"id":2572923,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":35187,"kind":"person","name":"Ignelzi Troy A.","position":1,"cik":"0001579829","reported_name":"Ignelzi Troy A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-09-10T20:58:56.000Z","date":"2021-09-08","kind":"sale","acquired":false,"shares":600,"price":121.01,"value":72606.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 15, 2021."}],"balance_after":18000,"source":{"system":"sec-edgar","filing":"0001593968-21-002107","document":"primary_01.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1579829/000159396821002107/primary_01.xml","form_type":"4"}},{"id":2572922,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":35187,"kind":"person","name":"Ignelzi Troy A.","position":1,"cik":"0001579829","reported_name":"Ignelzi Troy A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-09-10T20:58:56.000Z","date":"2021-09-08","kind":"exercise","acquired":true,"shares":600,"price":9.2,"value":5520.0,"ownership":{"direct":true},"balance_after":18600,"source":{"system":"sec-edgar","filing":"0001593968-21-002107","document":"primary_01.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1579829/000159396821002107/primary_01.xml","form_type":"4"}},{"id":2572921,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":35187,"kind":"person","name":"Ignelzi Troy A.","position":1,"cik":"0001579829","reported_name":"Ignelzi Troy A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-09-10T20:58:56.000Z","date":"2021-09-08","kind":"sale","acquired":false,"shares":7000,"price":116.16,"value":813120.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 15, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $116.11 to $116.24, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."}],"balance_after":18000,"source":{"system":"sec-edgar","filing":"0001593968-21-002107","document":"primary_01.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1579829/000159396821002107/primary_01.xml","form_type":"4"}},{"id":2572920,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":35187,"kind":"person","name":"Ignelzi Troy A.","position":1,"cik":"0001579829","reported_name":"Ignelzi Troy A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-09-10T20:58:56.000Z","date":"2021-09-08","kind":"exercise","acquired":true,"shares":7000,"price":9.2,"value":64400.0,"ownership":{"direct":true},"balance_after":25000,"source":{"system":"sec-edgar","filing":"0001593968-21-002107","document":"primary_01.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1579829/000159396821002107/primary_01.xml","form_type":"4"}},{"id":2593302,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":35187,"kind":"person","name":"Ignelzi Troy A.","position":1,"cik":"0001579829","reported_name":"Ignelzi Troy A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Option (right to buy)","published_at":"2021-08-23T20:16:10.000Z","date":"2021-08-20","kind":"exercise","acquired":false,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vested and became exercisable as to 1/4th of the shares underlying the option award on March 1, 2020, and continues to vest as to an additional 1/8th of the shares on each six month anniversary thereafter."}],"balance_after":189725,"derivative":{"exercise_price":9.2,"expiration_date":"2029-03-21","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001593968-21-002003","document":"primary_01.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1579829/000159396821002003/primary_01.xml","form_type":"4"}},{"id":2593301,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":35187,"kind":"person","name":"Ignelzi Troy A.","position":1,"cik":"0001579829","reported_name":"Ignelzi Troy A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-08-23T20:16:10.000Z","date":"2021-08-20","kind":"exercise","acquired":true,"shares":5000,"price":9.2,"value":46000.0,"ownership":{"direct":true},"balance_after":18000,"source":{"system":"sec-edgar","filing":"0001593968-21-002003","document":"primary_01.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1579829/000159396821002003/primary_01.xml","form_type":"4"}},{"id":2665588,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":35187,"kind":"person","name":"Ignelzi Troy A.","position":1,"cik":"0001579829","reported_name":"Ignelzi Troy A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Option (right to buy)","published_at":"2021-06-16T23:01:27.000Z","date":"2021-06-16","kind":"exercise","acquired":false,"shares":352,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests and becomes exercisable in thirty-six equal monthly installments beginning on April 1, 2019."}],"balance_after":1253,"derivative":{"exercise_price":9.2,"expiration_date":"2029-04-07","underlying":"Common Stock","underlying_shares":352},"source":{"system":"sec-edgar","filing":"0001593968-21-001633","document":"primary_01.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1579829/000159396821001633/primary_01.xml","form_type":"4"}},{"id":2665587,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":35187,"kind":"person","name":"Ignelzi Troy A.","position":1,"cik":"0001579829","reported_name":"Ignelzi Troy A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Option (right to buy)","published_at":"2021-06-16T23:01:27.000Z","date":"2021-06-14","kind":"exercise","acquired":false,"shares":900,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests and becomes exercisable in thirty-six equal monthly installments beginning on April 1, 2019."}],"balance_after":1605,"derivative":{"exercise_price":9.2,"expiration_date":"2029-04-07","underlying":"Common Stock","underlying_shares":900},"source":{"system":"sec-edgar","filing":"0001593968-21-001633","document":"primary_01.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1579829/000159396821001633/primary_01.xml","form_type":"4"}},{"id":2665586,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":35187,"kind":"person","name":"Ignelzi Troy A.","position":1,"cik":"0001579829","reported_name":"Ignelzi Troy A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Option (right to buy)","published_at":"2021-06-16T23:01:27.000Z","date":"2021-06-16","kind":"exercise","acquired":false,"shares":2248,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests and becomes exercisable in thirty-six equal monthly installments beginning on April 1, 2019."}],"balance_after":10031,"derivative":{"exercise_price":9.2,"expiration_date":"2029-03-28","underlying":"Common Stock","underlying_shares":2248},"source":{"system":"sec-edgar","filing":"0001593968-21-001633","document":"primary_01.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1579829/000159396821001633/primary_01.xml","form_type":"4"}},{"id":2665585,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":35187,"kind":"person","name":"Ignelzi Troy A.","position":1,"cik":"0001579829","reported_name":"Ignelzi Troy A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-06-16T23:01:27.000Z","date":"2021-06-16","kind":"sale","acquired":false,"shares":352,"price":128.4,"value":45196.8,"ownership":{"direct":true},"balance_after":13000,"source":{"system":"sec-edgar","filing":"0001593968-21-001633","document":"primary_01.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1579829/000159396821001633/primary_01.xml","form_type":"4"}},{"id":2665584,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":35187,"kind":"person","name":"Ignelzi Troy A.","position":1,"cik":"0001579829","reported_name":"Ignelzi Troy A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-06-16T23:01:27.000Z","date":"2021-06-16","kind":"exercise","acquired":true,"shares":352,"price":9.2,"value":3238.4,"ownership":{"direct":true},"balance_after":13352,"source":{"system":"sec-edgar","filing":"0001593968-21-001633","document":"primary_01.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1579829/000159396821001633/primary_01.xml","form_type":"4"}},{"id":2665583,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":35187,"kind":"person","name":"Ignelzi Troy A.","position":1,"cik":"0001579829","reported_name":"Ignelzi Troy A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-06-16T23:01:27.000Z","date":"2021-06-14","kind":"sale","acquired":false,"shares":900,"price":132.52,"value":119268.0,"ownership":{"direct":true},"balance_after":13000,"source":{"system":"sec-edgar","filing":"0001593968-21-001633","document":"primary_01.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1579829/000159396821001633/primary_01.xml","form_type":"4"}},{"id":2665582,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":35187,"kind":"person","name":"Ignelzi Troy A.","position":1,"cik":"0001579829","reported_name":"Ignelzi Troy A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-06-16T23:01:27.000Z","date":"2021-06-14","kind":"exercise","acquired":true,"shares":900,"price":9.2,"value":8280.0,"ownership":{"direct":true},"balance_after":13900,"source":{"system":"sec-edgar","filing":"0001593968-21-001633","document":"primary_01.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1579829/000159396821001633/primary_01.xml","form_type":"4"}},{"id":2665581,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":35187,"kind":"person","name":"Ignelzi Troy A.","position":1,"cik":"0001579829","reported_name":"Ignelzi Troy A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-06-16T23:01:27.000Z","date":"2021-06-16","kind":"sale","acquired":false,"shares":2248,"price":129.45,"value":291003.6,"ownership":{"direct":true},"balance_after":13000,"source":{"system":"sec-edgar","filing":"0001593968-21-001633","document":"primary_01.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1579829/000159396821001633/primary_01.xml","form_type":"4"}},{"id":2665580,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":35187,"kind":"person","name":"Ignelzi Troy A.","position":1,"cik":"0001579829","reported_name":"Ignelzi Troy A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-06-16T23:01:27.000Z","date":"2021-06-16","kind":"exercise","acquired":true,"shares":2248,"price":9.2,"value":20681.6,"ownership":{"direct":true},"balance_after":15248,"source":{"system":"sec-edgar","filing":"0001593968-21-001633","document":"primary_01.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1579829/000159396821001633/primary_01.xml","form_type":"4"}}],"next_cursor":"2021-06-16T23:01:27.000000Z,2665580"}